Recent studies have revealed that, in melanoma, the Raf/MEK/ERK inhibitor avutometinib downregulates RhoE, thereby relieving its inhibitory effect on the ROCK pathway, leading to activation of the RhoA/ROCK axis and subsequent upregulation of p-FAK, ultimately contributing to drug resistance (29). Here, MAP2K7 is linked to melanoma.